Aims-To investigate the expression of CD44 proteins in exfoliated urothelial cells and in tumour tissues from bladder cancer patients. A further objective was to evaluate the diagnostic potential ofthe changes observed in the expression of these proteins as a marker for non-invasive detection of bladder cancer. Methods-Naturally voided urine specimens were collected from 47 patients with bladder cancer or severe urothelial dysplasia (n = 3) and from a control group of 43 people with no evidence of neoplastic disease. Exfoliated urothelial cells floating in the urine were pelleted by centrifugation and lysed, and their constituent proteins extracted. The pattern of expression of CD44 proteins in each sample was examined by western blot analysis using a monoclonal antibody, Hermes 3, which recognises an epitope on the polypeptide backbone of the CD44 protein. Immunohistochemical studies were performed on neoplastic (n = 10) and normal (n = 4) bladder tissue specimens which were snap frozen in liquid nitrogen before examination with antibodies to CD44 gene products (CD44s and CD44v6). Results-Western blot analysis revealed several high molecular weight CD44 isoforms >160 kDa in urine cell lysates from 75% of patients with histologically confirmed bladder cancer and in two of the three patients with severe dysplasia. Such patterns were not detected in the urine cell pellets from any persons in the control group. Immunohistochemical studies of the tissue distribution of CD44s and CD44v6 showed that the differentiation and maturation ofthe epithelial cells in the normal bladder mucosa is accompanied by a decrease in CD44 protein expression.
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However, carcinoma cells overexpress standard and variant CD44 isoforms and continue to do so as they proceed through the thickened epithelial layer to the luminal surface and after they are shed into the urine. CD44, a widely distributed cell surface glycoprotein regarded as an extracellular adhesion molecule, is generated as various isoforms by alternative splicing of the products of at least 10 variant exons (CD44v) into a 37 kDa polypeptide backbone encoded by nine other, constitutively expressed, exons (CD44s) . The dominant isoform expressed in most normal cell types is the 90 kDa "standard form" produced by heavy glycosylation of the basic backbone, but differing quantities of the individual variant isoforms, which are much larger, can also be detected in several normal tissues and organs.45 The types of variants produced differ according to the site of origin of the tissue.
Conclusions
We and other groups have reported marked changes in CD44 gene splicing patterns in various types of human cancer.6-" These consist of a general increase in CD44 mRNA transcription with a progressive and disproportionate increase in variety and quantity of CD44v isoforms as malignancy advances. Immunohistochemical analysis has indicated that there is also a good correlation between the altered quantity and distribution of CD44 variant forms (CD44v), particularly CD44v6, and tumour progression.'012 These observations suggest the possibility that evaluation of CD44 gene activity could be useful in tumour diagnosis and evaluation of prognosis. In a study which is relevant to this clinical requirement, we recently reported abnormal transcription of the CD44 gene in exfoliated cancer cells in urine specimens." However, as mRNA is unstable and the technology for its analysis is specialised, routine tests based upon this analyte are not yet widely available. An assay based upon detection of CD44 protein may circumvent these problems. This led us to investigate, by western blotting, whether there were any specific abnormalities in CD44 protein profile of desquamated urothelial cells from bladder cancer patients which could be a useful marker for early diagnosis. We now present the results of a study of urine specimens from 44 bladder cancer patients, three patients with severe urothelial dysplasia, and 43 people without malignancy. In this report the data from western blotting procedures are compared with the results obtained with immunohistochemical techniques on the quantity and distribution of CD44s and CD44v6 isoforms in normal and cancerous bladder tissue biopsies. We chose to study the status of expression of exon v6 (exon 11) in these tumour samples because previous studies, cited above, had indicated that increased expression of this transcript/epitope correlates with tumour progression.
The results indicate that it should be possible to design an accurate test for bladder cancer based upon abnormal CD44 gene expression.
Methods

PREPARATION OF URINE CELL LYSATES
Naturallyvoided urine specimens ofabout 50 ml volume were collected from 47 patients with bladder cancer or severe urothelial dysplasia (37 male; 10 female) and 43 persons with no evidence of malignant disease (28 male; 15 female). The urine was collected into vessels containing 0-02 mM amidinophenylmethane sulphonyl fluoride (APMSF) (Sigma) and 1 mM EDTA (Sigma), as protease inhibitors, and kept on ice during transport to the laboratory.
The cell pellets collected by centrifugation at 3000 rpm for 15 min were lysed with 1:1 (wt/vol) of lysis buffer (20 mM tris [pH 8 0], 150 mM NaCl, 20 mM CHAPS, 2 mM EDTA, 0 04 mM APMSF, 20 ,ug/ml aprotinin) on ice for 15 minutes. This lysate was clarified by centrifugation (12 000 rpm, 15 min). The concentration of protein was determined (Bio-Rad protein assay kit) and adjusted to 5,g/lane by dilution with phosphate buffered saline containing 0-02 mM APMSF and 1 mM EDTA. Where necessary, samples were concentrated using a Microcon 30 membrane (Amicon).
Urine cell smears were prepared by washing the samples (3000 rpm) with Hank's buffered salt solution (HBSS), and spotting the cells onto poly l-lysine coated slides before fixing air dried preparations in 100% methanol at 4°C. All smears were stored at -20°C until required.
WESTERN BLOT ANALYSIS
Samples were boiled with gel loading buffer and subjected to 6% SDS-PAGE under reducing conditions. The separated proteins were electroblotted (100 mA, one hour) onto immobilon-P membranes (Millipore) using transfer buffer (48 mM tris, 39 mM glycine, 0-1% SDS, 20% methanol, pH 9 2). Nonspecific reactions were blocked with Tris buffered saline (TBS) containing 5% skimmed milk before the membrane was incubated with monoclonal antibody Hermes 3 (anti-CD44s; epitope encoded by exon 5) at 4°C overnight, and then with peroxidase conjugated antimouse IgG (Sigma; 1/1000 dilution) for one hour at room temperature. All antibodies were diluted in 5% skimmed milk in TBS and after each incubation the membrane was washed with TBS containing 0-1% Tween 20. Signals were detected by enhanced chemiluminescence with an ECL detection kit (Amersham). (fig 1) . However, in lysates from the control group (n = 43), bands were only detected in the 70 kDa to 90 kDa range with a few further minor components up to 120 kDa. Under the same assay conditions two human tumour cell lines (namely HT29, which is derived from a colonic carcinoma, and RT1 12, derived from a bladder carcinoma) also displayed a range of high molecular weight isoforms of CD44, well above the size of those seen in normal urine cells or in blood leucocytes.
On the basis of all of the above information, the presence of bands above 160 kDa was, for the further analysis of the data, defined as a positive criterion of malignancy. The table shows that samples from 33 of 44 patients (sensitivity = 75%) with histologically proven bladder cancer showed this positive pattern, whereas samples from all 41 asymptomatic volunteers and from two cystocopically negative patients with non-neoplastic disease showed the negative pattern, consisting of one to three bands smaller than 120 kDa. There were no false positives in this control group (specificity= 100%).
Among the test group of patients with proven malignancy or severe dysplasia, there were six with very early (pTaGl) tumours and four of these showed the positive high molecular weight pattern defined as positive. Of the three patients with severe urothelial dysplasia, two showed the positive western blotting pattern.
LOCALISATION OF CD44s AND CD44v6 IN NORMAL AND MALIGNANT BLADDER TISSUES
Immunohistochemical studies with monoclonal antibodies to the standard form of CD44 (Hermes 3) and to CD44v6 (2F10) showed differences in the location of the corresponding CD44 epitopes between normal and neoplastic bladder mucosa. Hermes 3 showed that in normal bladder epithelium (n = 4) CD44s protein can be detected only in the basal layers, and is also present in stromal cells, lymphocytes, vascular endothelial cells, and smooth muscle cells (fig 2A) . CD44v6 is likewise confined to the basal layers of normal epithelium but is not detectable in stromal cells ( fig 2B) . In neoplastic bladder specimens (n = 10) strong membranous immunostaining for CD44s and for CD44v6 was seen both in the basal cells of the malignant epithelium and in its more superficial cells (fig 2C and 2D ) in most specimens. In some areas there was a degree of regional heterogeneity in staining, but the trend towards staining of epithelial cells above the basal layer was still maintained.
PRESENCE OF CD44s AND CD44v PROTEINS IN EXFOLIATED BLADDER CELLS FROM URINE
Immunocytochemistry of urine cell smears showed that some cancer cells in urine from cancer patients stained positively for CD44v6 ( fig 3A) . This 
to occur in tumours"'1 is translated into unusual proteins, and that detection of these in exfoliated cells in naturally voided urine can be used to identify patients with bladder cancer with reasonable accuracy. With the current collection and processing conditions, a specificity of 100% and a sensitivity of 75% was achieved for the identification of patients with bladder cancer by western blotting. These are average figures for the overall range of stages and grades of bladder cancer among this test population and are better than published figures for cancer detection by urine cytology in similar pooled groups of patients.13 14 For accurate comparison, however, it would be necessary to use these different methods on the same group of patients. It also seems likely that a combination of the two methods of analysis could prove powerful in appropriate cases.
It is interesting to note that 66% of samples from patients with very early stage tumours (pTaGl) and severe dysplasia also showed the abnormal CD44 protein pattern seen in more advanced bladder malignancy. This suggests that the disturbances in the activity of this gene begin very early in the neoplastic process and may prove to be clinically useful.
Additionally, these results were obtained with a protocol involving collection of only a single specimen of urine from each person. As factors such as urine retention times and diurnal variations may influence these results, it is possible that the sensitivity of detection could increase with examination of repeat specimens. The criterion used for assigning western blotting results to cancer or non-neoplastic categories was the presence or absence of high molecular weight CD44 isoforms detectable by anti-CD44 monoclonal antibody Hermes 3, and no attempt was made to delineate which variants may or may not be present. However, it is possible that further work could identify a specific variant isoform which is preferentially increased in tumours and enable the development of an enzyme linked immunosorbent assay.
In our initial studies, we found that patients with frank haematuria or severe cystitis frequently showed only a strong band at -90 kDa, even when histological examination confirmed the presence of advanced bladder cancer. This band was most probably composed of CD44s derived from the large numbers of inflammatory leucocytes in the urine of such patients, and the absence of larger isoforms may have resulted from cleavage by proteases released from the dying polymorphs. Consequently, patients with cystitis or those with obvious signs of haematuria were excluded from the study. This technical issue does not diminish the potential value of large CD44 proteins as diagnostic markers for early detection of bladder neoplasia: patients with pyuria could first be treated to eradicate infection and then tested if symptoms persist, and ones with persistent haematuria should, in any case, be cystoscoped.
It should be noted that in our experience the immediate collection of the voided urine into a vessel containing powerful protease inhibitors is critically important. In our early work, we sometimes obtained negative results in batches of samples from patients with bladder cancer which were delayed in transit to the laboratory. Careful analysis showed that the conditions of specimen collection and transport are important. For best results we found that the urine should be: (1) collected in a vessel containing protease inhibitors; (2) kept chilled and transported to the laboratory the same day; (3) centrifuged and frozen (-70°C) until analysed, if not used immediately; and (4) analysed preferably within one month.
The exact mechanisms responsible for the lability of the samples between collection and analysis is yet to be determined. However, a recent study reported that the serum CD44 concentration in patients with gastric and colon cancer correlated with tumour burden and that the level decreased after surgical resection of the tumour in colon cancer patients. 
